Replies to post #710 on Synaptogenix Inc (SNPX)

[SF Wolf]

Zena, I think you are missing the point when you write:

“The share structure is such that insiders have the power to beat the snot out of retail. The liquidity is so low that market has no influence on share price.”

I believe the run up from $6.50 to $16.00 in the last month or so is precisely because a small group of retail investors who are following NTRP developments have been buying the stock.

The low float and lack of sellers, insider or retail, is constraining liquidly and thus buyers have been in charge.

This is all driven by the expectation of positive P2b results in the next 10 weeks. Also, with a NASDAQ up listing, possibly by the end of this month, options should be available. The stock then might be attractive to funds that have internal restraints on OTC investing.

If results meet positive expectations then retail buying will go into overdrive.

[F1ash]

You kinda misread the authors summary I believe.



"In my opinion, given the low float, it should be obvious that positive Phase 2b results will be highly accretive to the stock price. "

"Accretive is the process of accretion, which is growth or increase by gradual addition, in finance and general nomenclature. An acquisition is considered accretive if it adds to the item's value or corporation's earnings per share."
Accretive Definition | Investopedia


Your conclusion seems counter to the original post.

The great thing is NTRP is running a blinded placebo controlled trial. Imagine if they were targeting "cellular homeostasis" for example to treat Alzheimer's, and doing it in an unblinded trial.

"Homeostasis in a general sense refers to stability or balance in a system.

Oddly enough the reason that clinical trials like NTRP's should be blinded has to do with an Australian scam that was predicated on "balance".




https://www.google.com/amp/s/sciencebasedlife.wordpress.com/2011/09/02/exposing-the-power-balance-con/amp/

Running an unblinded non-placebo controlled trial is an invitation for investigator bias and misleading "practice effect". Thank goodness NTRP is running a proper trial that is actually a Phase 2b not a phase 2a who's primary endpoint is dose optimization that they hope will "fail quickly".

[Whatsupp]

It appears that you think NRV are insiders that control the stock. NRV is the non profit formed from BRNI as part of transferring the IP to NTRP. After split they have about 335000 shares. That is about 5% ownership of the outstanding 6.9 million shares.

[InTheTrenches]

XenaLives:

Have you listened to the BIOCeo presentation?

Dr. Alkon (beginning minute 10) reveals much more of the Neurotrope story than what the share structure reveals, in my opinion.

Regards

[Amatuer17]

Xena - i know you are very active investor in CNS biotechs - and expressed your views strongly.

So it is interesting to see the contrast of your views between 2 ALZ companies - NTRP and AVXL

-NTRP has finished enrollment of 148 patients in P2 trials as against just 32 patients in P1 trial for AVXL

- both of them have done r/s and have small number of shares o/s - NTRP can issue new 5 million shares and raised $100 million and create enough float - this it has more power to raise cash and limit dilution

- On safety - "Safety is not expected to be an issue. Soon after Bryostatin was first discovered, it was evaluated for use as a cancer treatment. Many clinical trials, comprising more than 1,500 individual patients, tested the safety of the compound, and found it to be universally well tolerated."

So what is your concern about safety?

- on IV vs Oral - yes IV is not convenient - but if the drug works, people will not mind taking one IV per week

So in the land of Alz - there are only few drugs being developed and these 2 companies are going in totally new direction (not beta amyloid approach)

With this background - why do you think NTRP is not a good investment candidate?